Therefore, inhibiting Akt/mTOR, as well as inhibiting PKM2, by MHY2245 treatment can increase autophagy, which may enhance antitumor effects of MHY2245 in ovarian cancer cells. Here, MTOR is linked to ovarian carcinoma.